Elutia Q1 net sales $6.7M; SimpliDerm up 55%; CanGarooRM FDA decision expected by June 2024

ELUTIA INC.

2023-Q3 EPS reported -$0.75 revenue$6,694,000

SimpliDerm net sales $3.6M (+55% YoY) driven by accelerated adoption in $1.6B breast reconstruction market.
CanGarooRM antibiotic-envelope 510(k) submission; positive FDA interactions; clearance anticipated Q2 2024.
Net loss $18.0M includes $9.6M non-cash warrant revaluation; adjusted EBITDA loss improved to $3.6M.
Cash balance $12.6M; preparing for CanGarooRM commercial launch in H2 2024.
Overall net sales $6.7M (+5% YoY); cardiovascular sales declined 56% due to LeMaitre distribution transition.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELUTIA INC. reported first quarter ended March 31, 2024 results: revenue $6.7 million, net income $18.0 million.

Period: first quarter ended March 31, 2024
Revenue: $6.7 million
Net income: $18.0 million
Result: reported results

Exact text from the filing

second half of this year. First Quarter 2024 Financial Results For the three-month period ended March 31, 2024, as compared to the same period of 2023: · Overall net sales were $6.7 million, an increase of 5%. · Net sales of SimpliDerm were $3.6 million, compared to $2.3 million, an increase of 55%, as customer awareness and acceptance accelerated within the $1.6

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

ELUTIA INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-059460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.